Emerald Health Pharmaceuticals (EHP) combines decades of life science and drug development experience with industry-leading expertise in cannabinoid science. Our focus is discovering, developing and commercializing proprietary cannabinoid-derived medicines that address significant unmet needs.
We believe that our novel cannabinoid new chemical entities (NCEs) have the potential to be developed into safe, effective pharmaceutical drugs, addressing unmet treatment needs in a wide range of diseases.
GLOBAL LEADERSHIP IN CANNABINOID RESEARCH
The novel research behind Emerald Health Pharmaceuticals’ proprietary molecules has been lead by eminent global researchers in the field of cannabinoid science. Their motivation has been to not only characterize the many powerful attributes and potential medical benefits of cannabinoids but to improve on nature’s accomplishments and create novel intellectual property.
EHP’s team has applied their cannabinoid expertise to the creation of novel molecules, or new chemical entities, that are based on the natural cannabinoid molecule but which they modify to affect additional validated receptors with the potential to enhance the impact of these drugs on targeted diseases. The novelty of these molecules qualifies them for composition of matter patents.
POTENTIAL FOR TREATING A WIDE RANGE OF DISEASES
EHP’s cannabinoid-derived product candidates have the potential to treat neurodegenerative, auto-immune, cardiovascular, metabolic and other diseases.
We have two proprietary cannabinoid-derived pharmaceutical drugs in preclinical development. One is for the treatment of multiple sclerosis (MS) and scleroderma, also known as systemic sclerosis (SSc). The other is for the treatment of Huntington’s disease (HD) and Parkinson’s disease (PD). Clinical trials are expected to start in 2018.
A PORTFOLIO OF PROPRIETARY PRODUCT CANDIDATES
EHP acquired two families of CBD and CBG derivative drugs (over 20 novel molecules including EHP-101 and EHP-102 along with composition of matter patents and patent applications).
Our lead product candidate, EHP-101, is derived from cannabidiol (CBD) and is being developed for the treatment of multiple sclerosis (MS) and scleroderma, also known as systemic sclerosis. Our second NCE, EHP-102, is derived from cannabigerol (CBG) and is being developed to treat Huntington’s disease and Parkinson’s disease.
EHP acquired these drugs from VivaCell Biotechnology España, a world leader in cannabinoid science, with which it also has a research agreement for continued scientific expertise and enhanced discovery capabilities.